Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

86.55 -0.80 (-0.91%)
Streaming Delayed Price Updated: 10:11 AM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
3 Big Reasons to Love DexCom (DXCM)
Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 15.6% to $87 per share. This was partly thanks to its solid quarterly results, and... 
Via StockStory
Topics Government Stocks
Exposures Political Product Safety US Equities
The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants... 
Via Benzinga
DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook
Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be... 
Via StockStory
Topics Economy
Exposures Supply Chain
DXC Tech Stock Slides On Sour Guidance, But Retail's Happy As Q4 Results Top Estimates
The company's bookings grew more than 20% for the second straight quarter, and the book-to-bill ratio exceeded one. 
Via Stocktwits
Topics Earnings
Exposures Financial
Earnings Scheduled For May 1, 2025
Via Benzinga
A Look Into DexCom Inc's Price Over Earnings
Via Benzinga
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO
From DexCom, Inc.
Via Business Wire
1 Healthcare Stock with Exciting Potential and 2 to Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 Product Safety US Equities
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
Dexcom's strong quarterly performance and innovative product pipeline signal continued leadership and expansion within the evolving diabetes technology market. 
Via MarketBeat
Topics Earnings
Exposures Financial Product Safety
What's Driving the Market Sentiment Around DexCom?
Via Benzinga
Uncover the latest developments among S&P500 stocks in today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance. 
Via Benzinga
Nasdaq 100 Leads Wall Street Rally As China Signals Openness To Fentanyl Talks, Easing Trade Tensions
U.S. stocks rose on hopes of China's willingness to negotiate a trade deal regarding fentanyl production. Tech stocks led the rally. 
Via Benzinga
Wall Street Eyes 9th Straight Day Of Gains, Apple Falls As Chinese Sales Disappoint: What's Driving Markets Friday?
U.S. stocks advanced across the board by midday Friday, with the S&P 500 eyeing its ninth consecutive day of gains—poised for the longest winning streak since May 2024. 
Via Benzinga
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday
Via Benzinga
2 Growth Stocks to Buy and Hold for a Decade
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
DexCom (NASDAQ:DXCM) Exceeds Q1 Expectations
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be... 
Via StockStory
Exposures Product Safety
Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program
From DexCom, Inc.
Via Business Wire
DexCom (DXCM) Q1 Earnings: What To Expect
Medical device company DexCom (NASDAQ:DXCM) will be reporting results tomorrow after market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday?
Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully... 
Via Benzinga
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U
From DexCom, Inc.
Via Business Wire
2 Cash-Producing Stocks That Stand Out and 1 to Keep Off Your Radar
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Exposures Product Safety
3 New ETFs Finding Early Traction With Investors
Markets have tumbled in 2025, but three funds launched this year have the potential to outshine even longer-established ETFs. 
Via MarketBeat
Topics ETFs
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
From Johnson Fistel, PLLP
Via Business Wire
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Tariffs, Trump, and Turmoil
Via The Motley Fool
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
What Does the Market Think About DexCom?
Via Benzinga
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.